The SH2 domain of Shc suppresses EGF-induced mitogenesis in a dominant negative manner
- PMID: 8545109
The SH2 domain of Shc suppresses EGF-induced mitogenesis in a dominant negative manner
Abstract
Recently, we have shown that an EGF-R-mutant lacking the autophosphorylation sites phosphorylates Shc and retains mitogenic activity. In this report, we have shown that in these cells, in response to EGF, Ras is fully activated with formation of the tyrosine-phosphorylated Shc-Grb2-mSOS complex without the receptor. This pointed out the importance of Shc in EGF-induced Ras activation. To investigate the mechanism of tyrosine phosphorylation of Shc by EGF-R, we carried out in vitro kinase assays using immunoprecipitated EGF-R and bacterially-expressed Shc proteins as substrates. The EGF-R phosphorylated Shc, but not the Shc SH2 mutant, lacking binding ability for phosphotyrosine. This suggests that intact Shc SH2 is essential for the full-length Shc to become phosphorylated, probably by inducing a conformational change in Shc. Thus a Shc SH2 peptide may inhibit competitively Shc phosphorylation. We microinjected the Shc SH2 domain into NIH3T3 cells overexpressing the EGF-R. Microinjected Shc SH2 greatly suppressed EGF-induced DNA synthesis. But microinjection of neither the Shc SH2 mutant nor PLC-gamma 1 SH2 had any effect. This suppressing effect was rescued by comicroinjection of the full-length Shc, suggesting Shc SH2 specifically suppressed the Shc pathway. Thus we concluded Shc phosphorylation is crucial, whereas receptor autophosphorylation is dispensable, in EGF-induced mitogenesis.
Similar articles
-
Potent SHC tyrosine phosphorylation by epidermal growth factor at low receptor density or in the absence of receptor autophosphorylation sites.Oncogene. 1994 Aug;9(8):2207-15. Oncogene. 1994. PMID: 8036006
-
Autophosphorylation mutants of the EGF-receptor signal through auxiliary mechanisms involving SH2 domain proteins.Oncogene. 1994 Dec;9(12):3457-65. Oncogene. 1994. PMID: 7970705
-
N-Shc: a neural-specific adapter molecule that mediates signaling from neurotrophin/Trk to Ras/MAPK pathway.Oncogene. 1996 Sep 19;13(6):1111-21. Oncogene. 1996. PMID: 8808684
-
Role of Shc in the activation of Ras in response to epidermal growth factor and nerve growth factor.Oncogene. 1994 Dec;9(12):3483-91. Oncogene. 1994. PMID: 7970708
-
Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling.Biochem J. 2003 Dec 1;376(Pt 2):457-64. doi: 10.1042/BJ20030668. Biochem J. 2003. PMID: 14498832 Free PMC article.
Cited by
-
Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation.Mol Cell Biol. 1998 Dec;18(12):7192-204. doi: 10.1128/MCB.18.12.7192. Mol Cell Biol. 1998. PMID: 9819406 Free PMC article.
-
Bifurcation of cell migratory and proliferative signaling by the adaptor protein Shc.J Cell Biol. 1999 Dec 27;147(7):1561-8. doi: 10.1083/jcb.147.7.1561. J Cell Biol. 1999. PMID: 10613912 Free PMC article.
-
Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells.Br J Cancer. 2001 Jul 20;85(2):303-11. doi: 10.1054/bjoc.2001.1910. Br J Cancer. 2001. PMID: 11461094 Free PMC article.
-
A novel pathway from phosphorylation of tyrosine residues 239/240 of Shc, contributing to suppress apoptosis by IL-3.EMBO J. 1996 Nov 15;15(22):6197-204. EMBO J. 1996. PMID: 8947042 Free PMC article.
-
Kinase activation through dimerization by human SH2-B.Mol Cell Biol. 2005 Apr;25(7):2607-21. doi: 10.1128/MCB.25.7.2607-2621.2005. Mol Cell Biol. 2005. PMID: 15767667 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous